LRRK2 as a therapeutic target in Parkinson’s disease
2010; Wiley; Volume: 18; Issue: 4 Linguagem: Inglês
10.1111/j.1468-1331.2010.03305.x
ISSN1468-1331
AutoresEng‐King Tan, Anthony H.V. Schapira,
Tópico(s)Neurological diseases and metabolism
ResumoEuropean Journal of NeurologyVolume 18, Issue 4 p. 545-546 EDITORIAL LRRK2 as a therapeutic target in Parkinson's disease E. K. Tan, E. K. Tan Departments of Neurology, Singapore General Hospital, National Neuroscience Institute Duke-NUS Graduate Medical School, SingaporeSearch for more papers by this authorA. H. Schapira, A. H. Schapira University Department of Clinical Neurosciences, Institute of Neurology, Queen Square, University College London, London, UK (e-mail: [email protected])Search for more papers by this author E. K. Tan, E. K. Tan Departments of Neurology, Singapore General Hospital, National Neuroscience Institute Duke-NUS Graduate Medical School, SingaporeSearch for more papers by this authorA. H. Schapira, A. H. Schapira University Department of Clinical Neurosciences, Institute of Neurology, Queen Square, University College London, London, UK (e-mail: [email protected])Search for more papers by this author First published: 29 December 2010 https://doi.org/10.1111/j.1468-1331.2010.03305.xCitations: 10Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1 Tan EK, Schapira AH. New LRRK2 variants identified in Parkinson's disease. Eur J Neurol 2011; 18: 369–370. 2 Schapira AH. The importance of LRRK2 mutations in Parkinson disease. Arch Neurol 2006; 63: 1225–1228. 3 Abdalla-Carvalho CB, Santos-Rebouças CB, Guimarães BC, et al. Genetic analysis of LRRK2 functional domains in Brazilian patients with Parkinson's disease. Eur J Neurol 2010; 17: 1479–1481. 4 Tan EK, Skipper LM. Pathogenic mutations in Parkinson disease. Hum Mutat 2007; 28: 641–653. 5 Tan EK, Zhao Y, Skipper L, et al. The lrrk2 gly2385arg variant is associated with parkinson's disease: genetic and functional evidence. Hum Genet 2007; 120: 857–863. 6 West AB, Moore DJ, Biskup S, et al. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci U S A 2005; 102: 16842–16847. 7 Smith WW, Pei Z, Jiang H, Dawson VL, Dawson TM, Ross CA. Kinase activity of mutant lrrk2 mediates neuronal toxicity. Nat Neurosci 2006; 9: 1231–1233. 8 Lu YW, Tan EK. Molecular biology changes associated with LRRK2 mutations in Parkinson's disease. J Neurosci Res 2008; 86: 1895–1901. 9 Lee BD, Shin JH, VanKampen J, et al. Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nat Med 2010; 16: 998–1000. 10 Li Y, Liu W, Oo TF, et al. Mutant lrrk2 (r1441g) bac transgenic mice recapitulate cardinal features of parkinson's disease. Nat Neurosci 2009; 12: 826–828. 11 Ng CH, Mok SZ, Koh C, et al. Parkin protects against LRRK2 G2019S mutant-induced dopaminergic neurodegeneration in Drosophila. J Neurosci 2009; 29: 11257–11262. 12 Schapira AH, Tolosa E. Molecular and clinical prodrome of Parkinson disease: implications for treatment. Nat Rev Neurol. 2010; 6: 309–317. 13 Schapira AH. Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Lancet Neurol. 2008; 7: 97–109. 14 Gegg ME, Cooper JM, Chau KY, Rojo M, Schapira AH, Taanman JW. Mitofusin-1 and Mitofusin-2 are ubiquitinated in a PINK1/parkin dependent manner upon induction of mitophagy. Hum Mol Genet 2010; 19: 4861–4870. 15 Dagda RK, Cherra SJ III, Kulich SM, Tandon A, Park D, Chu CT. Loss of PINK1 function promotes mitophagy through effects on oxidative stress and mitochondrial fission. J Biol Chem. 2009; 284: 13843–13855. 16 Whitworth AJ, Pallanck LJ. The PINK1/Parkin pathway: a mitochondrial quality control system? J Bioenerg Biomembr 2009; 41: 499–503. 17 Deng J, Lewis PA, Greggio E, Sluch E, Beilina A, Cookson MR. Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase. Proc Natl Acad Sci U S A 2008; 105: 1499–1504. 18 Sheng D, Qu D, Kwok KH, et al. Deletion of the WD40 domain of LRRK2 in Zebrafish causes Parkinsonism-like loss of neurons and locomotive defect. PLoS Genet. 2010; 6: e1000914. Citing Literature Volume18, Issue4April 2011Pages 545-546 ReferencesRelatedInformation
Referência(s)